ANIP
NASDAQ
US
ANI Pharmaceuticals, Inc. - Common Stock
$74,21
▼ $-1,75
(-2,30%)
Vol. 276K
11
Punteggio di Qualità
ok
Analisi approfondita
2/5
ok
Ricavi ✓
Utile netto ✓
>IPO ✗
Cap. mercato
$1.8B
P/E
43,7
ROE
8,8%
Margine
4,9%
D/E
122,64
Beta
0,50
52W
$53–$100
Consenso Wall Street
14 analisti · Apr 20265
Acquisto forte
7
Compra
2
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 100,0%
Prossimo report
Mag 07, 2026
Stima EPS: $1,48
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $1,48 | — | — |
| Dic 2025 | $2,04 | $2,33 | +$0,29 |
| Set 2025 | $1,79 | $2,04 | +$0,25 |
| Giu 2025 | $1,45 | $1,80 | +$0,35 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M |
| Utile netto | — | -$10.3M | $15.7M | $8.5M | $26.6M | $27.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -2.3% | -2.3% | -2.3% | -2.3% | 8.8% | 8.8% |
| P/E (TTM) | — | — | — | — | 45.48 | 43.72 |
| Net Margin | 4.0% | -1.4% | -1.4% | -1.4% | 4.9% | 4.9% |
| Gross Margin | 64.7% | 61.1% | 61.1% | 61.1% | 61.1% | 61.1% |
| D/E Ratio | 134.65 | 134.65 | 134.65 | 134.65 | 122.64 | 122.64 |
| Current Ratio | 2.54 | 2.54 | 2.54 | 2.54 | 2.58 | 2.58 |
Rapporti chiave
ROA (TTM)
3,1%
P/S (TTM)
2,15
P/B
2,7
EPS (TTM)
$1,94
CF/Share
$4,03
Crescita ricavi 3A
+41,7%
52W High
$99,50
52W Low
$52,74
$52,74
Intervallo 52 settimane
$99,50
Salute finanziaria
Flusso di cassa libero
$29.0M
Debito netto
$331.4M
Liquidità
$285.6M
Debito totale
$617.0M
Aggiornato al Dic 31, 2025
Як ANIP виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка ANIP vs аналоги Pharmaceuticals
P/E
43,7
▲
96%
sopra
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
2,2
▼
57%
sotto
peer
(5,0)
vs Peer
vs Settore
Sottovalutato
P/B
2,7
▲
28%
sopra
peer
(2,1)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ANIP vs аналоги Pharmaceuticals
ROE
8,8%
▲
116%
sopra
peer
(-54,3%)
vs Peer
vs Settore
Top livello
Net margin
4,9%
▲
110%
sopra
peer
(-47,4%)
vs Peer
vs Settore
Sotto media
Валова маржа
61,1%
▼
10%
sotto
peer
(68,3%)
vs Peer
vs Settore
Debole
ROA
3,1%
▲
108%
sopra
peer
(-37,4%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя ANIP vs аналоги Pharmaceuticals
D/E ratio
122,6
▲
7864%
sopra
peer
(1,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
2,6
▼
23%
sotto
peer
(3,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,5
▼
47%
sotto
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ANIP
ANIP
Mediana peer
Industria
ANIP прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ANIP vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
COOK MEREDITH
General Counsel · Mar 13
500 shs
MUTZ CHRISTOPHER
Officer · Mar 13
3162 shs
ROWLAND THOMAS ANDREW
Officer · Mar 11
4772 shs
DAVIS KRISTA
Officer · Mar 09
6572 shs
MUTZ CHRISTOPHER
Officer · Mar 09
5723 shs
CAREY STEPHEN P.
Chief Financial Officer · Mar 05
7312 shs
CAREY STEPHEN P.
Chief Financial Officer · Mar 05
3312 shs
WALSH PATRICK D
Director · Mar 03
6000 shs
GUTWERG ORI
Officer · Mar 03
2060 shs
MUTZ CHRISTOPHER
Officer · Mar 02
417 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 25,98%Blackrock Inc.
11,88%
$193.8M
Vanguard Group Inc
5,82%
$95.0M
State Street Corporation
3,24%
$53.0M
Global Alpha Capital Manage…
2,63%
$43.0M
Millennium Management Llc
2,41%
$39.3M
Aggiornato al Dic 31, 2025